Shuko Harada

Medical Genetics

619 19th St S
Birmingham, AL 35249

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 83 publications

Complete Remission to Imatinib in a Myeloid Neoplasm with Basophilia and PRKG2::PDGFRA Gene Fusion: A Case Report.

Complete Remission to Imatinib in a Myeloid Neoplasm with Basophilia and PRKG2::PDGFRA Gene Fusion: A Case Report.

Journal: Acta haematologica

Published: May 03, 2026

Revisiting HER2-negative breast cancer in the era of HER2-low and HER2-ultralow expression: Assessment of interobserver variability.

Revisiting HER2-negative breast cancer in the era of HER2-low and HER2-ultralow expression: Assessment of interobserver variability.

Journal: Breast (Edinburgh, Scotland)

Published: April 09, 2026

Clinical and Molecular Characterization of Clear Cell Adenocarcinoma of the Urinary Tract: A Multi-Institutional Study.

Clinical and Molecular Characterization of Clear Cell Adenocarcinoma of the Urinary Tract: A Multi-Institutional Study.

Journal: The American journal of surgical pathology

Published: March 03, 2026

MPRIP::PDGFRB fusion identified in a male patient with a myeloid/lymphoid neoplasm with eosinophilia.

MPRIP::PDGFRB fusion identified in a male patient with a myeloid/lymphoid neoplasm with eosinophilia.

Journal: Annals of hematology

Published: January 16, 2026

An Undifferentiated Epithelioid and Spindle Cell Neoplasm of the Uterus Harboring a SMARCA2::CREM Fusion: A Case Report and Review of the Literature.

An Undifferentiated Epithelioid and Spindle Cell Neoplasm of the Uterus Harboring a SMARCA2::CREM Fusion: A Case Report and Review of the Literature.

Journal: International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists

Published: September 30, 2025

Cutaneous Rosai-Dorfman disease with near-complete response to the MEK inhibitor cobimetinib.

Cutaneous Rosai-Dorfman disease with near-complete response to the MEK inhibitor cobimetinib.

Journal: JAAD case reports

Published: September 11, 2025

Systemic Xanthogranuloma or Erdheim-Chester disease: A systematic review re-examining the classification challenge.

Systemic Xanthogranuloma or Erdheim-Chester disease: A systematic review re-examining the classification challenge.

Journal: British journal of haematology

Published: September 09, 2025

Indeterminate Dendritic Cell Histiocytosis Harboring ETV3::NCOA2 Translocation with Complete Metabolic Response to MEK Inhibition.

Indeterminate Dendritic Cell Histiocytosis Harboring ETV3::NCOA2 Translocation with Complete Metabolic Response to MEK Inhibition.

Journal: The British journal of dermatology

Published: August 09, 2025

Case Report: KMT2A amplification in two adult patients with B-cell acute lymphoblastic leukemia.

Case Report: KMT2A amplification in two adult patients with B-cell acute lymphoblastic leukemia.

Journal: Frontiers in oncology

Published: June 30, 2025

Association between p16INK4A expression and a treatment response to CDK4/6 inhibitor in advanced breast carcinoma.

Association between p16INK4A expression and a treatment response to CDK4/6 inhibitor in advanced breast carcinoma.

Journal: Human pathology

Published: June 10, 2025

Primary Ewing Sarcoma of the Kidney: Clinicopathologic and Molecular Study of 24 Patients Including a Rare EWSR1::ETV4 Fusion.

Primary Ewing Sarcoma of the Kidney: Clinicopathologic and Molecular Study of 24 Patients Including a Rare EWSR1::ETV4 Fusion.

Journal: The American journal of surgical pathology

Published: May 28, 2025

Hepatic adenomas in males: Is molecular characterization helpful in guiding its management?

Hepatic adenomas in males: Is molecular characterization helpful in guiding its management?

Journal: Human pathology

Published: March 01, 2025

Showing 1-12 of 83

Last Updated: 09/26/2026